Publications by authors named "Tamer Abd Elhamid Elbedewy"
Article Synopsis
- The study examined immune thrombocytopenic purpura (ITP), an autoimmune condition leading to low platelet counts, and investigated the expression levels of immunological markers CD63 and CD64 in different groups of subjects.
- Researchers analyzed samples from 180 participants, including ITP patients, individuals with other types of thrombocytopenia, and healthy controls, using techniques like RT-qPCR and flow cytometry.
- Results showed that both CD63 and CD64 were significantly elevated in ITP patients compared to others, suggesting they could serve as effective biomarkers for diagnosing and assessing ITP severity.
Background: Multiple myeloma (MM) is a malignant incurable disease characterized by monoclonal plasma cell increase associated with renal impairment. Evaluation of neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), hemoglobin/red cell distribution width (HB/RDW), interleukin-20 (IL-20), and vascular endothelial growth factor-A (VEGFA) in patients with MM (with or without renal impairment) as prognostic and severity indicators.
Research Design And Methods: A cross-sectional study was conducted on sixty MM patients with renal impairment, sixty MM patients without renal impairment, and sixty subjects (control group).
Background: Immune thrombocytopenic purpura (ITP) is an acquired autoimmune hematologic disorder with heterogeneous bleeding manifestations. Many biomarkers such as interleukin-37 (IL-37), vascular endothelial growth factor A (VEGFA), and transforming growth factor-β1 (TGFß1) have a role in immunity, inflammation, and megakaryopoiesis.
Methods: In the present study, immunoassay of interleukin-37 as well as the gene expression of vascular endothelial growth factor A and transforming growth factor-β1 were done in 60 primary ITP patients, 60 thrombocytopenia patients, and 60 healthy volunteers.